Guslandi M
Gastroenterology Unit, S. Raffaele Hospital, Milan, Italy.
Int J Colorectal Dis. 1999 Nov;14(4-5):261-2. doi: 10.1007/s003840050221.
Patients with mild to moderate active colitis who are treated with mesalazine plus transdermal nicotine reportedly suffer fewer relapses than patients treated with mesalazine plus oral prednisone. A long-term follow-up period was carried out to confirm this. Thirty patients with remission of distal colitis after therapy with the above treatment schedules were monitored for 12 months (Rachmilewitz' activity index plus endoscopy). Relapsed patients were retreated in a cross-over fashion. After 12 months recurrences were observed in 14 of 15 patients initially treated with steroids and in 7 of 15 subjects who were had received transdermal nicotine (P = 0.007, Fisher's test). A higher proportion of relapsed patients from the prednisone group, after successful retreatment with nicotine patches, remained in remission after 6 months (20%) than relapsed patients who switched to steroid treatment (57%). Our present results confirm the concept that nicotine-induced remission of ulcerative colitis lasts longer than that obtained by oral corticosteroids.
据报道，与接受美沙拉嗪加口服泼尼松治疗的患者相比，接受美沙拉嗪加经皮尼古丁治疗的轻至中度活动性结肠炎患者复发次数更少。为此进行了长期随访。对30例经上述治疗方案治疗后远端结肠炎缓解的患者进行了12个月的监测（拉赫米列维茨活动指数加内镜检查）。复发患者采用交叉方式重新治疗。12个月后，最初接受类固醇治疗的15例患者中有14例复发，接受经皮尼古丁治疗的15例患者中有7例复发（P = 0.007，费舍尔检验）。泼尼松组复发患者在成功接受尼古丁贴片重新治疗后，6个月后仍处于缓解状态的比例（20%）高于转而接受类固醇治疗的复发患者（57%）。我们目前的结果证实了这样一个概念，即尼古丁诱导的溃疡性结肠炎缓解持续时间比口服皮质类固醇获得的缓解持续时间更长。
